vorinostat — CareFirst (Caremark)

Initial criteria

• Member has a diagnosis of cutaneous T-cell lymphoma (e.g., mycosis fungoides or Sézary syndrome)

Reauthorization criteria

• No evidence of unacceptable toxicity or disease progression while on current regimen

Approval duration

12 months